Drug Targets – News and Features

According to a study, activating the Hippo tumor suppressor pathway helps prevent moles from mutating into melanoma.

This article will discuss advances in fragment-based drug discovery and will highlight some examples of recent successes in this area.

In this interview, Rolland Carlson, PhD, CEO of Immunexpress, discusses sepsis and the company’s FDA cleared SeptiCyte® RAPID test, as well as a take on the company’s differentiated value and outlook.

Researchers have demonstrated that a novel targeted therapy could be an effective treatment option for neuroblastoma, a deadly pediatric cancer.

Researchers have just publicly released some of the first data showing the specific types of neurons and other brain cells that die off or otherwise change in Alzheimer’s disease, using cutting-edge techniques to categorize individual cells based on what their genes do.

Researchers have used a novel strategy to study host cell proteins that contribute to the multiplication of the Lassa virus, which causes a severe hemorrhagic fever disease. This could lead to potential new drug targets for treating the disease.

Researchers have discovered a link between two of the most common genetic changes that cause cells to become cancerous.

Neuroscientists have been investigating the symphony of signals created within a region of the brain called the basolateral amygdala to better understand how they contribute to negative feelings such as anxiety and fear.

A new study by scientists at the Salk Institute and Rutgers University reveals the molecular structure of HIV Pol, a large protein that is key for human immunodeficiency virus (HIV) replication.

A study describes the first-ever high-resolution three-dimensional structure of an endogenous reverse transcriptase.